The latest cancer drugs news
Browsing: Cancer Drug News
Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for adult relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r ALL)
This content is password-protected. To view it, please enter the password below. Password:
FDA approves selpercatinib for RET fusion-positive thyroid cancer
On June 12, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo,…
Access to targeted lung cancer drug durvalumab is cost-prohibitive globally
Many countries with national healthcare systems or payers such as insurance companies use cost-effectiveness analyses…
FDA grants accelerated approval to selpercatinib for paediatric patients two years and older with RET-altered metastatic thyroid cancer or solid tumours
On May 29, 2024, the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo,…
FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma
On May 30, 2024, the US Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno…
Recent FDA committee vote could speed multiple myeloma drug approval
A U.S. Food and Drug Administration committee voted unanimously in April to approve a new…
Integration of pharmacies with physician practices has little impact on cancer drug expenditures
Integration of pharmacies with physician practices, where on-site pharmacies open at physician practice locations, is…
New study further illuminates ability of cancer drug to lower blood sugar
University of Oklahoma researchers in the USA have deepened their understanding of a drug’s ability…
Scientists uncover promising treatment target for resistant glioblastoma
For many patients with a deadly type of brain cancer called glioblastoma, chemotherapy resistance is…
FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer
On April 29, 2024, the Food and Drug Administration granted traditional approval to tisotumab vedotin-tftv…